INDV

Indivior PLC

Add to Watchlist

Advanced Chart

11.750

+0.180(+1.560%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

11.770

Open

11.610

VWAP

11.62

Vol

822.12K

Mkt Cap

1.47B

Low

11.360

Amount

9.56M

EV/EBITDA(TTM)

Total Shares

134.08M

1.39B

EV/OCF(TTM)

P/S(TTM)

1.28

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

249.90M

-16.14%

0.257

-19.51%

247.97M

-19.23%

0.253

-53.09%

242.30M

-18.96%

0.240

-45.45%

Estimates Revision

The market is revising Downward the revenue expectations for Indivior PLC (INDV) for FY2025, with the revenue forecasts being adjusted by -4.08% over the past three months. During the same period, the stock price has changed by -3.69%.

Revenue Estimates for FY2025

Revise Downward

-4.08%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-20%

In Past 3 Month

Stock Price

Go Down

-3.69%

In Past 3 Month

6 Analyst Rating

23.32% Upside

Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 14.49 USD with a low forecast of 12.92 USD and a high forecast of 15.98 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

23.32% Upside

Current: 11.750

Low

12.92

Averages

14.49

High

15.98

23.32% Upside

Current: 11.750

Low

12.92

Averages

14.49

High

15.98

Piper Sandler

David Amsellem

Buy

Maintains

$16 → $13

2025-03-06

Reason

Piper Sandler

David Amsellem

Price Target

$16 → $13

2025-03-06

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on Indivior to $13 from $16 and keeps an Overweight rating on the shares. The firm says it would view the appointment of Joe Ciaffoni as CEO as an encouraging development.

Piper Sandler

David Amsellem

Buy

Reiterates

$15 → $16

2024-10-25

Reason

Piper Sandler

David Amsellem

Price Target

$15 → $16

2024-10-25

Reiterates

Buy

Reason

Piper Sandler raised the firm's price target on Indivior to $16 from $15 and keeps an Overweight rating on the shares after Q3 earnings. Though the optics of multiple downward revisions to 2024 guidance are undoubtedly "messy," Sublocade is growing, particularly in the context of significant underpenetration of long-acting injectable buprenorphine modalities, Piper told investors in a research note.

Piper Sandler

David Amsellem

Buy

Reiterates

$22 → $15

2024-10-11

Reason

Piper Sandler

David Amsellem

Price Target

$22 → $15

2024-10-11

Reiterates

Buy

Reason

Piper Sandler lowered the firm's price target on Indivior to $15 from $22 and keeps an Overweight rating on the shares. Indivior again reduced its 2024 expectations for Sublocade, this time due to competitive dynamics associated with Braeburn's Brixadi, variability across criminal justice system accounts, and inventory headwinds, the analyst tells investors in a research note. The firm says management's problem is the inability to set appropriate expectations as opposed to "something intrinsically troubling" about Sublocade.

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$20 → $16

2024-10-11

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$20 → $16

2024-10-11

Maintains

Strong Buy

Reason

Craig-Hallum lowered the firm's price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls "a disappointing update." The company lowering FY24 net revenue guidance was "entirely driven by worsening fundamentals for Sublocade," notes the analyst, who calls Sublocade "the chief value driver for Indivior." There is hope for stabilization, but the firm is taking a "show me" approach with estimates, adding that it still believes the stock is "far too cheap" and "will work nicely as estimates bottom."

Piper Sandler

David Amsellem

Buy

Reiterates

$22

2024-09-13

Reason

Piper Sandler

David Amsellem

Price Target

$22

2024-09-13

Reiterates

Buy

Reason

Piper Sandler

David Amsellem

Buy

Initiates

$22

2024-07-23

Reason

Piper Sandler

David Amsellem

Price Target

$22

2024-07-23

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Indivior PLC (INDV.O) is 9.31, compared to its 5-year average forward P/E of 23.86. For a more detailed relative valuation and DCF analysis to assess Indivior PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

23.86

Current PE

9.31

Overvalued PE

69.99

Undervalued PE

-22.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

5.88

Current EV/EBITDA

5.54

Overvalued EV/EBITDA

8.35

Undervalued EV/EBITDA

3.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.12

Current PS

1.39

Overvalued PS

2.77

Undervalued PS

1.47